Patents by Inventor Michal Schweiger

Michal Schweiger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prostate cancer markers
    Patent number: 9540697
    Abstract: The invention relates to the identification and selection of novel genomic regions (biomarker) and the identification and selection of novel genomic region combinations which are hypermethylated in subjects with prostate cancer compared to subjects without prostate cancer. Nucleic acids which selectively hybridize to the genomic regions and products thereof are also encompassed within the scope of the invention as are compositions and kits containing said nucleic acids and nucleic acids for use in diagnosing prostate cancer. Further encompassed by the invention is the use of nucleic acids which selectively hybridize to one of the genomic regions or products thereof to monitor disease regression in a patient and the efficacy of therapeutic regimens.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: January 10, 2017
    Assignee: Max-Plank-Gesellschaft Zur Foerderung Der Wissenschaften E.V.
    Inventors: Michal Schweiger, Hans Lehrach, Stefan Boerno, Thorsten Schlomm, Holger Sueltmann, Guido Sauter
  • PROSTATE CANCER MARKERS
    Publication number: 20140051082
    Abstract: The invention relates to the identification and selection of novel genomic regions (biomarker) and the identification and selection of novel genomic region combinations which are hypermethylated in subjects with prostate cancer compared to subjects without prostate cancer. Nucleic acids which selectively hybridize to the genomic regions and products thereof are also encompassed within the scope of the invention as are compositions and kits containing said nucleic acids and nucleic acids for use in diagnosing prostate cancer. Further encompassed by the invention is the use of nucleic acids which selectively hybridize to one of the genomic regions or products thereof to monitor disease regression in a patient and the efficacy of therapeutic regimens.
    Type: Application
    Filed: April 19, 2012
    Publication date: February 20, 2014
    Inventors: Michal Schweiger, Hans Lehrach, Stefan Sörnö, Thorsten Schlomm, Holger Sültmann, Guido Suter